Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DUBLIN, Ireland, Feb. 29, 2016 -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9 at 10:40AM ET.
Dr. Heffernan will provide an overview of Nexvet’s pioneering developments in the field of biopharmaceuticals for companion animals in the therapeutic areas of pain, inflammation, allergy and immuno-oncology.
A live webcast of the presentation can be accessed by visiting the investor relations section of Nexvet’s website at http://ir.nexvet.com. A replay of the webcast will be available for 30 days following the presentation.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and has acquired biomanufacturing capabilities in Ireland.
Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Jessica Burns Berry & Company Public Relations +1 212-253-8881 [email protected]
